# ClinicalTrials.gov record NCT05530577

> PeptideScanner retained ClinicalTrials.gov record NCT05530577 at 2026-07-30T18:23:09.828Z. Its registry update date was 2025-08-22, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05530577-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-08-22
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05530577-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct05530577-semaglutide-v1.json
- Content SHA-256: `707c90d58cf756a2dcff4a5991ed79faf725a36473d1acfc05b55e9a9757f04a`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT05530577 ([`ctg-observation-nct05530577-2025-08-22-df642c5c9e22`](#source-ctg-observation-nct05530577-2025-08-22-df642c5c9e22))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05530577 at 2026-07-30T18:23:09.828Z. Its registry update date was 2025-08-22, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05530577-2025-08-22-df642c5c9e22`](#source-ctg-observation-nct05530577-2025-08-22-df642c5c9e22))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05530577 at 2026-07-30T18:23:09.828Z. Its registry update date was 2025-08-22, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05530577-2025-08-22-df642c5c9e22`](#source-ctg-observation-nct05530577-2025-08-22-df642c5c9e22))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05530577-2025-08-22-df642c5c9e22`](#source-ctg-observation-nct05530577-2025-08-22-df642c5c9e22))

## Sources

<a id="source-ctg-observation-nct05530577-2025-08-22-df642c5c9e22"></a>
- **ClinicalTrials.gov record NCT05530577 · retained source version 2025-08-22:df642c5c9e22b5d594a66a319d237ca8ff07182ce371f0fe035b85385b184787** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05530577) (`ctg-observation-nct05530577-2025-08-22-df642c5c9e22`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05530577." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct05530577-semaglutide-v1.json SHA-256: 707c90d58cf756a2dcff4a5991ed79faf725a36473d1acfc05b55e9a9757f04a.